<?xml version="1.0" encoding="UTF-8"?>
<p id="para0033">Chloroquine, as a drug extensively utilized in anti-malaria and autoimmune diseases, has been found to be a potential broad-spectrum antiviral agent 
 <xref rid="bib0100" ref-type="bibr">[100]</xref>. It can prevent viral infections via elevating the endosomal pH needed for virus-cell fusion and disturbing the glycosylation of SARS-CoV cell receptors 
 <xref rid="bib0101" ref-type="bibr">[101]</xref>. Gao et al. revealed that chloroquine was effective in the therapy of COVID-19-associated pneumonia 
 <xref rid="bib0102" ref-type="bibr">[102]</xref>. Wang and coworkers also conducted 
 <italic>in vitro</italic> study, and they found that it is an ideal candidate antiviral drug against SARS-CoV-2 infection in Vero E6 cells with EC50 value of around 1 μM 
 <xref rid="bib0088" ref-type="bibr">[88]</xref>. Although several trials had verified that chloroquine suppresses the exacerbation of COVID-19, the optimal dosage of chloroquine will require to be evaluated in future trials 
 <xref rid="bib0102" ref-type="bibr">[102]</xref>.
</p>
